{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:33:31Z","timestamp":1778931211900,"version":"3.51.4"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess in real life whether two-drug regimens (2-DRs) given 4\u20135\u2009days a week in virally suppressed patients can maintain viral suppression over 48 and 96\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This observational single-centre study enrolled all patients who initiated an intermittent 2-DR between 01\/01\/2016 and 30\/06\/2019. The primary outcome was the rate of virological failure (VF), defined as confirmed plasma viral load (pVL) \u226550\u2009copies\/mL or single pVL \u226550\u2009copies\/mL followed by ART change at week 48 (W48) and W96. Secondary outcomes were the 2-DR intermittent strategy success rate (pVL &amp;lt;50\u2009copies\/mL with no ART change), change in CD4 count, CD4\/CD8 ratio and rate of residual viraemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-five patients were included; 67\/85 (79%) were men, median age\u2009=\u200957\u2009years (IQR\u2009=\u200950\u201363), CD4 nadir\u2009=\u2009233\u2009cells\/mm3 (110\u2013327), ART duration\u2009=\u200921\u2009years (13\u201324), duration of virological suppression\u2009=\u20096.5\u2009years (3.7\u201310.8) and CD4 count\u2009=\u2009658\u2009cells\/mm3 (519\u2013867). Intermittent 2-DRs consisted of integrase strand transfer inhibitor (INSTI)\/NNRTI (58%), INSTI\/NRTI (13%), two NRTIs (11%), PI\/NRTI (7%) and other combinations (11%). The median follow-up was 90\u2009weeks (IQR\u2009=\u200964\u2013111). Overall, four VFs occurred, leading to a virological success rate of 98.8% (95% CI\u2009=\u200993.6\u2013100) at W48 and 95.3% (95% CI\u2009=\u200988.4\u201398.7) at W96. Resuming the same 2-DR 7\u2009days a week led to viral resuppression in three patients, whereas the M184V mutation emerged in one patient, leading to ART modification. There was no significant change in the CD4 count or residual viraemia rate, but a small increase in the CD4\/CD8 ratio (P\u2009=\u20090.009) occurred over the study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This observational study shows the potential for intermittent 2-DRs to maintain a high virological success rate, which should be assessed in larger prospective randomized studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab108","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T20:12:39Z","timestamp":1615925559000},"page":"1893-1897","source":"Crossref","is-referenced-by-count":2,"title":["Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"first","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-0010","authenticated-orcid":false,"given":"Basma","family":"Abdi","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giota","family":"Lourida","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Faycal","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Schneider","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Seang","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Agher","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Simon","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathia","family":"Soulie","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh-Patrick","family":"Le","sequence":"additional","affiliation":[{"name":"Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, AP-HP, INSERM, UMRS 1144, Universit\u00e9 de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, AP-HP, IAME, INSERM, UMRS 1137, Universit\u00e9 de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"2021070808220144800_dkab108-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","article-title":"HIV","volume":"392","author":"Ghosn","year":"2018","journal-title":"Lancet"},{"key":"2021070808220144800_dkab108-B2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070808220144800_dkab108-B3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2021070808220144800_dkab108-B4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/QAD.0000000000001476","article-title":"Individualized antiretroviral therapeutic approaches: less can be more","volume":"31","author":"Katlama","year":"2017","journal-title":"AIDS"},{"key":"2021070808220144800_dkab108-B5","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/S2352-3018(16)30054-6","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2\/3 trial","volume":"3","year":"2016","journal-title":"Lancet HIV"},{"key":"2021070808220144800_dkab108-B6","author":"Landman","year":"2019"},{"key":"2021070808220144800_dkab108-B7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkx434","article-title":"Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial","volume":"73","author":"de Truchis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021070808220144800_dkab108-B8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1468-1293.2009.00719.x","article-title":"A large French prospective cohort of HIV-infected patients: the Nadis Cohort","volume":"10","author":"Pugliese","year":"2009","journal-title":"HIV Med"},{"key":"2021070808220144800_dkab108-B9","doi-asserted-by":"crossref","first-page":"e576\u201387.","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"2021070808220144800_dkab108-B10","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021070808220144800_dkab108-B11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgar.2019.08.010","article-title":"Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-na\u00efve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety","volume":"20","author":"Cento","year":"2020","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/7\/1893\/38693611\/dkab108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/7\/1893\/38693611\/dkab108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:02:44Z","timestamp":1625763764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/7\/1893\/6225958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,14]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab108","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,4,14]]}}}